Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts
- 1 June 2010
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 298 (6), H2201-H2207
- https://doi.org/10.1152/ajpheart.00815.2009
Abstract
We previously demonstrated that several epoxyeicosatrienoic acids (EETs) produce reductions in myocardial infarct size in rats and dogs. Since a recent study demonstrated the release of opioids in mediating the antinociceptive effect of 14,15-EET, we hypothesized that endogenous opioids may also be involved in mediating the cardioprotective effect of the EETs. To test this hypothesis, we used an in vivo rat model of infarction and a rat Langendorff model. In the infarct model, hearts were subjected to 30 min occlusion of the left coronary artery and 2 h reperfusion. Animals were treated with 11,12-EET or 14,15-EET (2.5 mg/kg) alone 15 min before occlusion or with opioid antagonists [naloxone, naltrindole, nor-binaltorphimine (nor-BNI), and d-Phe-Cys-Tyr-d-Trp-Om-Thr-Pen-Thr-NH2 (CTOP), a nonselective, a selective δ, a selective κ, and a selective μ receptor antagonist, respectively] 10 min before EET administration. In four separate groups, antiserum to Met- and Leu-enkephalin and dynorphin-A-(1–17) was administered 50 min before the 11,12-EET administration. Infarct size expressed as a percent of the area at risk (IS/AAR) was 63.5 ± 1.2, 45.3 ± 1.0, and 40.9 ± 1.2% for control, 11,12-EET, and 14,15-EET, respectively. The protective effects of 11,12-EET were abolished by pretreatment with either naloxone (60.5 ± 1.8%), naltrindole (60.8 ± 1.0%), nor-BNI (62.3 ± 2.8%), or Met-enkephalin antiserum (63.2 ± 1.7%) but not CTOP (42.0 ± 3.0%). In isolated heart experiments, 11,12-EET was administered to the perfusate 15 min before 20 min global ischemia followed by 45 min reperfusion in control hearts or in those pretreated with pertussis toxin (48 h). 11,12-EET increased the recovery of left ventricular developed pressure from 33 ± 1 to 45 ± 6% ( P < 0.05) and reduced IS/AAR from 37 ± 4 to 20 ± 3% ( P < 0.05). Both pertussis toxin and naloxone abolished these beneficial effects of 11,12-EET. Taken together, these results suggest that the major cardioprotective effects of the EETs depend on activation of a Gi/o protein-coupled δ- and/or κ-opioid receptor.Keywords
This publication has 30 references indexed in Scilit:
- Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dogAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K + Channels and p42/p44 MAPK PathwayCirculation Research, 2004
- Cross-talk of opioid peptide receptor and ?-adrenergic receptor signalling in the heartCardiovascular Research, 2004
- Sustained exogenous administration of Met5-enkephalin protects against infarction in vivoAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- An opioid basis for early-phase isoflurane-induced hypotension in ratsLife Sciences, 2003
- Activation of δ- and κ-opioid receptors by opioid peptides protects cardiomyocytes via KATPchannelsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Cardiac synthesis, processing, and coronary release of enkephalin-related peptidesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2000
- Localization of preproenkephalin mRNA in rat heart: selective gene expression in left ventricular myocardiumAmerican Journal of Physiology-Heart and Circulatory Physiology, 1998
- Pertussis toxin, but not tyrosine kinase inhibitors, abolishes effects of U-50488H on [Ca2+]i in myocytesAmerican Journal of Physiology-Cell Physiology, 1997
- Tissue Distribution of Opioid Receptor Gene Expression in the RatBiochemical and Biophysical Research Communications, 1996